Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 97
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT01299506 | Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide | ||
| NCT03427268 | Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment | ||
| NCT00780975 | A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer | ||
| NCT00580112 | An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer | ||
| NCT00404521 | A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors | ||
| NCT02163720 | Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) | ||
| NCT02684318 | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | ||
| NCT03117361 | Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide | ||
| NCT02566993 | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | ||
| NCT02454972 | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | ||
| NCT04358237 | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. | ||
| NCT02451007 | Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors | ||
| NCT01149681 | Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis | ||
| NCT04382066 | Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19 | ||
| NCT02394015 | Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC | ||
| NCT05705167 | Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA) | ||
| NCT05572476 | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer | ||
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | ||
| NCT01970540 | Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | ||
| NCT05153239 | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | ||
| NCT00113607 | An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer | ||
| NCT05835609 | PM534 Administered Intravenously to Patients With Advanced Solid Tumors | ||
| NCT00147212 | ET 743 (Yondelis) in Men With Advanced Prostate Cancer | ||
| NCT04305548 | Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma | ||
| NCT00027508 | Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma | ||
| NCT02533674 | Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors | ||
| NCT07644039 | Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies | ||
| NCT00050427 | A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer | ||
| NCT01735071 | Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer | ||
| NCT02825420 | Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients | ||
| NCT02367924 | Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma | ||
| NCT02448537 | A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas | ||
| NCT00796120 | An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) | ||
| NCT02398058 | Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) | ||
| NCT00884845 | Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors | ||
| NCT00579501 | Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | ||
| NCT00884286 | Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma | ||
| NCT00229203 | A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma | ||
| NCT03070964 | A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma | ||
| NCT01846611 | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | ||
| NCT01951157 | A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients | ||
| NCT01314599 | Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome | ||
| NCT02210364 | Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). | ||
| NCT00900562 | Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy | ||
| NCT06088290 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | ||
| NCT06524583 | Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour | ||
| NCT05121740 | Extension Study in a Cohort of Adult Patients With COVID-19 Infection | ||
| NCT01831089 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | ||
| NCT01222767 | Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy | ||
| NCT01876043 | Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial |
